Geplante Studien
| Name | Titel |
|---|---|
| AGO-Ovar 2.33 / ANITA | A phase III, randomized, double-blinded trial of platinum-based chemotherapy followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal or peritoneal cancer and platinum treatment-free interval (TFIp) > 6 months |
| AGO-Ovar 2.34 / MIROVA | A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in BRCA wild-type, folate receptor alpha (FRα)-positive recurrent ovarian cancer eligible for platinum-based chemotherapy. |
| AGO-ZX 3 / BEATcc | A Randomized Phase III Trial of Platinum Chemotherapy plus Paclitaxel with Bevacizumab and Atezolizumab versus Platinum Chemotherapy plus Paclitaxel and Bevacizumab in Metastatic (stage IVB), Persistent or Recurrent Carcinoma of the Cervix |
| CO-3810-101 / LIO-1 | A Phase 1b/2, Open-Label Study to Evaluate the Safety and Efficacy of Lucitanib in Combination With Nivolumab in Patients With an Advanced, Metastatic Solid Tumor |
| DUO-E | A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E) |
| ENGOT-Cx12 / GCT1015-07 | A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin versus Investigator’s Choice Chemotherapy in Second or Third Line Recurrent or Metastatic Cervical Cancer |
| ENGOT-EN6 / RUBY | A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) plus Carboplatin-Paclitaxel versus Placebo plus Carboplatin-Paclitaxel in Patients with Recurrent or Primary Advanced Endometrial Cancer |
| ENGOT-EN9 | A Phase 3 Randomized, Open-Label, Study of Pembrolizumab Plus Lenvatinib Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma |
| ENGOT-ov53 / VITALIA | A phase III, multicentre, randomized, double-blind, placebo-controlled trial of DCVAC/OvCa added to standard of care induction and maintenance therapy in patients with relapsed platinum sensitive ovarian, fallopian tube, and primary pertioneal carcinoma |
| IMGN853-416 / MIRASOL | A Randomized, Open-label, Phase 3 Study of Mirvetuximab Soravtansine vs. Investigator´s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression |
| IMGN853-0417 / SORAYA | A Phase 3, Single Arm Study of Mirvetuximab Soravtansine in Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers with High Folate Receptor-Alpha Expression |
| NEWTON | A MULTICENTER, OPEN-LABEL PHASE II TRIAL OF A NEW CUSTOMIZED DOSING (RATIONAL ADJUSTMENT OF DOSE TO REDUCE ADVERSE REACTIONS “RADAR” DOSING) OF NIRAPARIB AS MAINTENANCE THERAPY IN PLATINUM SENSITIVE OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL RECURRENT CANCER PATIENTS. |
| RAD-18-001 | A phase 1 study to evaluate the dose, safety and tolerability of an intraperitoneal α-emitting radionuclide therapy (Radspherin®) in patients with platinum sensitive recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma with peritoneal carcinomatosis following complete surgical resection |